Treats essential hypertension. ANDA 79070, held by Aurobindo Pharma. Perindopril Erbumine.
As of Nov 16, 2026, ANDA 79070 (Perindopril Erbumine), held by Aurobindo Pharma, was first approved by FDA on Nov 10, 2009, with 5 approved supplements and 0 published complete response letters.
Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 2009 | Original application | Approved |
| Perindopril Erbumine2MG · tablet;oral | Perindopril Erbumine | Rx |
| Perindopril Erbumine4MG · tablet;oral | Perindopril Erbumine | Rx |
| Perindopril Erbumine8MG · tablet;oral | Perindopril Erbumine | Rx |
| Jan 10, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 20, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 20, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 17, 2011 | Supplement 3Labeling | Approved | None posted |
| Jul 21, 2011 | Supplement 2Labeling | Approved | None posted |
| Nov 10, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters